



EDITED BY
EDMUND S. KOSTEWICZ
MARIA VERTZONI
HEATHER A.E. BENSON
MICHAEL S. ROBERTS

ORAL DRUG DELIVERY FOR MODIFIED RELEASE FORMULATIONS



WILEY

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[Preface](#)

[List of Contributors](#)

[Part I: Understanding of Physiology and Anatomy –
Factors Influencing Drug Release and Absorption from
MR Formulations](#)

[1a Composition of Gastric Fluids Under Fasting and
Fed Conditions](#)

[1a.1 Gastric Volume](#)

[1a.2 Gastric Acid](#)

[1a.3 Buffer Capacity](#)

[1a.4 Mucus/Viscosity](#)

[1a.5 Enzymes](#)

[1a.6 Surface Tension](#)

[1a.7 Osmolality](#)

[1a.8 Duodenogastric Reflux](#)

[References](#)

[1b Composition of the Small Intestinal Contents
Under Fasting and Fed Conditions](#)

[1b.1 Small Intestinal Volume](#)

[1b.2 pH Profile Along the Small Intestine](#)

[1b.3 Composition of the Luminal Contents](#)

[1b.4 Other Characteristics of Small Intestinal
Fluids](#)

1b.5 Influence of Age, Gender, and Disease on the Small Intestinal Composition

References

1c The Luminal Environment in the Proximal Colon

1c.1 Volume of Luminal Contents

1c.2 Luminal pH Values

1c.3 Buffer Capacity

1c.4 Characteristics of Liquid Fraction of Contents

1c.5 Concluding Remarks

References

2 Gastrointestinal Transit and Hydrodynamics Under Fasting and Fed Conditions

2.1 Introduction

2.2 Imaging Techniques Used for Assessment of Transit Times and Hydrodynamics

2.3 Oral Cavity and Esophagus

2.4 Stomach

2.5 Small Intestine

2.6 Large Intestine

2.7 Whole Gut Transit Time

2.8 Therapy-Related Effects on GI Transit

2.9 Motility Disorders Affecting the GI Transit of Oral Dosage Forms

2.10 Patient-Related Effects on GI Transit

2.11 Conclusion

References

3 Intestinal Epithelium and Drug Transporters

3.1 Introduction: Oral Drug Absorption General Mechanisms and Influencing Factors

[3.2 Expression of Drug Transporters in the Intestinal Epithelium](#)

[3.3 Uptake Transporters Present at the Intestinal Level](#)

[3.4 Regional Distribution of Uptake Transporters](#)

[3.5 Efflux Transporters at the Intestinal Level](#)

[3.6 Regional Distribution of Efflux Transporters](#)

[3.7 Impact of the Regional Distribution of Enzymes and Transporters in the Intestine on the Enzyme/Transporter Interplay](#)

[3.8 Species Differences in Regional Expression of Uptake and Efflux Transporters](#)

[3.9 Models for Regional Assessment of Intestinal Permeability](#)

[3.10 Use of PBPK to Integrate Formulation and Permeation Knowledge](#)

[3.11 Impact of Regional Solubility and Permeability Along the Intestine](#)

[3.12 Formulation Excipients and Their Potential Modulatory Effects on Transporters](#)

[3.13 Other Confounding Factors Affecting Drug Intestinal Absorption](#)

[3.14 Drug-Drug Interactions](#)

[3.15 Conclusion and Future Challenges](#)

[References](#)

[4 The Interplay Between Drug Release and Intestinal Gut-Wall Metabolism](#)

[4.1 The Role of Gut Wall Metabolism in Determining Oral Bioavailability](#)

[4.2 Factors Affecting Gut Wall Metabolism](#)

[4.3 Preclinical and Clinical *In Vivo* and *In Situ* Models for Studying Intestinal Metabolism](#)

[4.4 *In Vitro* Assays for Studying Intestinal Metabolism](#)

[4.5 Models for Studying Bacterial Degradation](#)

[4.6 *In Vitro*–*In Vivo* Extrapolation of Metabolic Clearance and *In Silico* Models for Predicting *In Vivo* Gut Wall Metabolism](#)

[4.7 Oral Extended-Release Formulations and Gut Wall Metabolism](#)

[4.8 Excipient Effects on Gut Wall Metabolism](#)

[4.9 Considerations for Intestinal Metabolism in Special Populations](#)

[4.10 Summary](#)

[References](#)

[Part II: Design of MR Formulations – Considerations, Mechanisms and Technologies](#)

[5 Preformulation Considerations for Design of Oral Modified-Release Products](#)

[5.1 Introduction](#)

[5.2 Purpose of MR Formulations](#)

[5.3 Means to Obtain MR Drug Products](#)

[5.4 Ionization Constant – \$pK_a\$](#)

[5.5 Lipophilicity](#)

[5.6 Solubility](#)

[5.7 Chemical Stability](#)

[5.8 Solid State Characterization](#)

[5.9 Compatibility with Excipients](#)

[5.10 Permeability and Metabolism](#)

[5.11 Regional Absorption](#)

[5.12 Microbial Stability](#)

[5.13 Quality by Design \(QbD\) for MR formulations](#)

[5.14 Conclusions](#)

[References](#)

[6 The Application of Biopharmaceutics Classification Systems to Modified-Release Formulations](#)

[6.1 Introduction](#)

[6.2 The Use of Biopharmaceutics Classification Systems in Oral Drug Development](#)

[6.3 The Application of Classification Systems to MR Drug Product Development - An Evidence-Based Approach](#)

[6.4 Summary](#)

[References](#)

[7 Technologies and Mechanisms for Oral Modified Release by Monolithic and Multiparticulate Delivery Systems](#)

[7.1 Introduction](#)

[7.2 Mechanism of Drug Release](#)

[7.3 Manufacturing Processes](#)

[7.4 Formulation Screening and Characterization](#)

[7.5 Conclusions and Perspectives](#)

[References](#)

[8 Lipid-based Formulations](#)

[8.1 Introduction](#)

[8.2 Mechanisms of Lipid-mediated Improvements in Bioavailability](#)

[8.3 Lipid-based Formulations for Controlled Release](#)

[8.4 Design of Lipid-based Formulations](#)

[8.5 Formulation Screening and Characterization](#)

[8.6 Industrial Considerations on LBF](#)

[8.7 Emerging Applications of Lipid-based Formulations](#)

[8.8 Conclusions](#)

[References](#)

[9 Strategies for MR Formulation Development:](#)

[9.1 Introduction](#)

[9.2 Technologies](#)

[9.3 Characterization](#)

[9.4 Stability of Drug Carrier](#)

[9.5 Silica-based Materials for the Modified Release of Poorly Soluble Drugs - *In Vitro/In Vivo* Applications](#)

[9.6 Toxicological Assessment](#)

[9.7 Conclusions and Future Directions](#)

[References](#)

[10 Hot-Melt Extrusion Technology for Modified-Release \(MR\) Formulation Development](#)

[10.1 Introduction](#)

[10.2 HME Technology Overview](#)

[10.3 General Considerations in Developing MR Dosage Forms Using HME Processing](#)

[10.4 Material Considerations for MR-HME Application](#)

[10.5 Dosage Form Design and Case Studies](#)

[10.6 Characterization of HME Products](#)

[10.7 Summary](#)

[References](#)

[11 Gattefosse: Strategies for MR Formulation Development – Lipids](#)

[11.1 Introduction](#)

[11.2 Lipids Used in SR Matrix](#)

[11.3 Processing Lipid SR Matrix](#)

[11.4 Understanding Drug Release from Lipid Matrix](#)

[11.5 Characterizing Lipid SR Matrix](#)

[11.6 Conclusions](#)

[References](#)

[12 Polymethacrylates for Modified-Release Formulations](#)

[12.1 Introduction](#)

[12.2 Polymethacrylate Polymers and Their Application in Modified-Release Dosage Forms](#)

[12.3 Protective Coatings](#)

[12.4 Gastro-Resistant Coatings](#)

[12.5 EUDRACAP™ Functional Ready-To-Fill Capsules for Fast Track Development of Sensitive Drugs](#)

[12.6 Modified-Release Technology](#)

[12.7 Modified-Release Formulations for Gastrointestinal Targeting](#)

[12.8 Matrix Tablets as an Alternative to Modified-Release Multiparticulate Dosage Forms](#)

12.9 Alcohol-Resistant Formulation Concepts
with EUDRAGIT[®] Polymers

12.10 Conclusion

References

13 Strategies for Modified Release Oral
Formulation Development

13.1 Introduction

13.2 Controlled-Release Drug Delivery Systems

13.3 Dual-Release Drug Delivery Systems and
Fixed-Dose Combination

13.4 Site-Specific Drug Delivery Systems

13.5 Conclusion/Future Perspectives

References

Part III: Evaluation of MR Formulations

14 Dissolution Equipment and Hydrodynamic
Considerations for Evaluating Modified-Release
Behavior

14.1 Introduction

14.2 Compendial Dissolution Equipment

14.3 USP Apparatus 7 – Reciprocating Holder

14.4 Noncompendial Dissolution Equipment

14.5 Summary and Conclusion

References

15 The Role and Applications of Dissolution Media
for the Investigation of Modified-Release
Formulations

15.1 Introduction

15.2 Compendial Media

15.3 Biorelevant Media

15.4 Biphasic Dissolution Media

15.5 Summary and Outlook

References

16 Biorelevant Dissolution Testing to Forecast the *In Vivo* Performance of Modified-Release Formulations

16.1 Introduction

16.2 Factors Affecting the *In Vivo* Performance of MR Products

16.3 Drug-Related Aspects

16.4 Formulation-Related Aspects

16.5 Biorelevant *In Vitro* Dissolution Test Methods

16.6 General Remarks on Dissolution Media

16.7 General Remarks on Dissolution Test Devices

16.8 Dissolution Test Methods for the Simulation of Regional Transit Conditions

16.9 Criteria for the Selection of a Suitable Biorelevant *In Vitro* Dissolution Method

16.10 Conclusion

References

17 *In Vitro* and *Ex Vivo* Dissolution Tests for Considering Dissolution in the Lower Intestine

17.1 Introduction

17.2 Dissolution Tests for pH-responsive Delivery Systems

17.3 Dissolution Tests for Enzyme-triggered Delivery Systems

17.4 Conclusion

References

18 Preclinical Evaluation – Animal Models to Evaluate MR Formulations

18.1 Introduction

18.2 When to Use Nonclinical Models in the Development of Modified-release Formulations

18.3 Physiological Factors in Animals Used to Investigate Modified-release Formulations

18.4 Intestinal Site-specific Administration in Animals

18.5 Evaluation of Modified-release Formulations in Animal Models

18.6 Conclusions

References

19 *In Vitro*–*In Vivo* Correlations for Modified Release Formulations

19.1 Introduction

19.2 Definitions of IVIVC

19.3 Correlation Levels

19.4 Considerations in IVIVC Development

19.5 IVIVC Models

19.6 Predictability of IVIVC

19.7 Use of IVIVC

19.8 Limitations of an IVIVC

19.9 Conclusion

Acknowledgment

References

20 Application of the Simcyp Population-based PBPK Simulator to the Modelling of MR Formulations

20.1 Introduction

[20.2 The ADAM Oral Absorption Model](#)

[20.3 Handling of Modified Release Formulations](#)

[20.4 System Information](#)

[20.5 MR Case Studies/Examples](#)

[20.6 Conclusion](#)

[References](#)

[21 PK-Sim[®] for Modeling Oral Drug Delivery of Modified-Release Formulations](#)

[21.1 General Introduction on PK-Sim[®] and MoBi[®]](#)

[21.2 Gastrointestinal Transit and Absorption Model](#)

[21.3 Formulations Available in PK-Sim[®]](#)

[21.4 Dissolved Form](#)

[21.5 Zero and First-order Release and Lint80 Release](#)

[21.6 Weibull](#)

[21.7 Particle Dissolution](#)

[21.8 Dissolution Media and Transit Times](#)

[21.9 Case Studies](#)

[21.10 Outlook](#)

[References](#)

[22 Clinical Evaluation – *In Vivo* Bioequivalence Assessment of MR Formulations](#)

[22.1 Introduction/Historical Background](#)

[22.2 Clinical Evaluation of New and Generic Modified-Release Formulations](#)

[22.3 Summary](#)

References

23 US Regulatory Considerations for Modified Release Products

23.1 Introduction

23.2 Clinical Development Programs for Nongeneric MR Dosage Forms

23.3 Considerations for Clinical Development Programs for Generic MR Products

23.4 Studies to Support Postapproval Changes for MR Products

23.5 Summary

Disclaimer

References

24 Regulatory Assessment, European Perspective

24.1 Introduction

24.2 Quality of Oral Extended-Release Products

24.3 Quality by Design in Pharmaceutical Development

24.4 Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms

24.5 Concluding Remarks

References

25 Industry Perspectives for the Evaluation of MR Formulations

25.1 Introduction

25.2 Commercially Marketed MR Products – Historical Trends and Emerging Themes

25.3 Early-stage MR Product Development

25.4 Current Themes for Industrial MR Product Evaluation: (1) Dissolution Acceleration

[25.5 Current Themes for Industrial MR Product Evaluation: \(2\) Hydro-ethanolic Studies](#)

[25.6 Conclusion](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 2

[Table 2.1 Techniques suitable for the determination of gastrointestinal tran...](#)

[Table 2.2 Diseases and disorders affecting GI motility.](#)

[Table 2.3 The effect of age on the regional and whole gut transit times of S...](#)

Chapter 3

[Table 3.1 Summary of the key characteristics of the uptake and efflux transp...](#)

[Table 3.2 Common MR formulation excipients modulatory effects on transporter...](#)

Chapter 4

[Table 4.1 Comparison of methods for estimating \$F_G\$ *in vivo* and *in situ*.](#)

[Table 4.2 Comparison of *in vitro* methods for investigating intestinal contri...](#)

[Table 4.3 Reported values of microsomal scalars for proximal intestine in ra...](#)

Chapter 5

[Table 5.1 Differences in applications of Quality by Test \(QbT\) and Quality b...](#)

Chapter 6

[Table 6.1 61 Successfully marketed modified-release products.](#)

[Table 6.2 55 Drugs with relative colon fraction absorbed \(\$F_{relColon}\$ \) data.](#)

[Table 6.3 Solubility boosting approaches used in extended-release dosage for...](#)

[Table 6.4 The properties of two locally acting steroids, and their commercia...](#)

Chapter 7

[Table 7.1 Examples of commercial MR products exploiting multiunit delivery s...](#)

Chapter 8

[Table 8.1 Biopharmaceutical effects of oral lipid-based formulations.](#)

[Table 8.2 Selected examples of commercial formulations employing LBF.](#)

[Table 8.3 Common LBF excipients and their classification.](#)

[Table 8.4 Comparison of varying lipid excipient characteristics.](#)

[Table 8.5 The lipid formulation classification system \(LFCS\).](#)

[Table 8.6 Comparison of the three *in vitro* characterization techniques in te...](#)

Chapter 10

[Table 10.1 Marketed Pharmaceutical Products manufactured using HME process....](#)

[Table 10.2 Commonly used excipients for MR application and specific consider...](#)

[Table 10.3 Commonly observed problems with HME products and strategies to mi...](#)

Chapter 11

[Table 11.1 Solid lipid excipients for sustained release drug delivery system...](#)

[Table 11.2 Effect of formulation parameters and process on drug release.](#)

[Table 11.3 Good *in vitro-in vivo* correlation for lipid-based dosage fo...](#)

[Table 11.4 Pharmacokinetic parameters of Compritol[®] 888 ATO and market ...](#)

Chapter 12

[Table 12.1 Poly\(meth\)acrylate product range suitable for MR formulation deve...](#)

[Table 12.2 Polymer application levels for different modified-release functio...](#)

[Table 12.3 Polymer application levels for different modified-release functio...](#)

[Table 12.4 Application levels of different EUDRAGIT[®] types for sealing,...](#)

[Table 12.5 Dissolution results of automatically filled EUDRACAP[™] enteric emp...](#)

[Table 12.6 Aqueous and solvent-based standard formulations for sustained rel...](#)

[Table 12.7 Parameters for in-process curing of EUDRAGIT[®] RL/RS 30 and E...](#)

[Table 12.8 Dissolution profiles of Benazepril HCl Pellets coated with EUDRAT...](#)

Chapter 13

[Table 13.1 Examples of excipients used for LMPs.](#)

[Table 13.2 Composition of the TravelGuard[®] DuoCap[™] product.](#)

[Table 13.3 Examples of products that need DRcaps[®] protection.](#)

Chapter 15

[Table 15.1 Composition of SGF_{sp} \(without pepsin\) and SIF_{sp} \(without pancreat...](#)

[Table 15.2 Overview of the identified biorelevant dissolution media.](#)

[Table 15.3 Exemplary composition of Levels I and II media of the fasted stat...](#)

[Table 15.4 Experimental conditions for monolithic dosage forms using a gradi...](#)

[Table 15.5 Representative composition \(mM\) of aspirates from human jejunal f...](#)

[Table 15.6 Examples of the compositions of biphasic dissolution media.](#)

Chapter 16

[Table 16.1 Comparison of the capabilities of different physiologically rele...](#)

[Table 16.2 Dissolution conditions applied in USP apparatus III for the simu...](#)

Chapter 17

[Table 17.1 Simulated gastrointestinal parameters in TIM-1 and TIM-2 dynamic](#)

[Table 17.2 Drug release studies utilizing human fecal contents in batch cult...](#)

Chapter 18

[Table 18.1 Physiological parameters of the gastrointestinal tract of selecte...](#)

[Table 18.2 Distribution of net bags in the gastrointestinal tract of animals...](#)

[Table 18.3 Suggested nonclinical species to be used in the evaluation of dif...](#)

Chapter 20

[Table 20.1 Internal and external predictive performance of various IVIVC mod...](#)

Chapter 21

[Table 21.1 Fitted parameters of the Weibull function served as input for the...](#)

Chapter 22

[Table 22.1 Pharmacokinetic parameters to be evaluated in bioequivalence asse...](#)

Chapter 23

[Table 23.1 Different levels of postapproval changes \[1, 38\].](#)

Chapter 25

[Table 25.1 Comparison of mean PK parameters for IR and CR formulations of PF...](#)

[Table 25.2 FDA dissolution requirements for alcohol studies.](#)

List of Illustrations

Chapter 1c

[Figure 1c.1 Individual values for the aspirated volume \(A\), % aqueous fracti...](#)

Chapter 2

[Figure 2.1 Esophageal retention rate \(%\) of capsules as a function of postur...](#)

[Figure 2.2 Mean gastric volume \$\pm\$ SEM before and after intake of 240 ml of wat...](#)

[Figure 2.3 Individual gastric content volumes \(ml\) before and after administ...](#)

[Figure 2.4 Box plot of gastric residence times after fasted and fed administ...](#)

[Figure 2.5 Schematic of types of plasma concentration profiles that can be o...](#)

[Figure 2.6 Comparison of plasma concentrations \(\$\bullet\$ \), gastrointestinal tablet ...](#)

[Figure 2.7 Orocaecal transit time of four groups of subjects who consumed a ...](#)

[Figure 2.8 Mass transport of a magnetically labeled microcapsule of about 1-...](#)

[Figure 2.9 Gastrointestinal localization pattern of magnetically marked nond...](#)

[Figure 2.10 Age effects on basal acid output \(BAO\) and peak acid output \(PAO...](#)

Chapter 3

[Figure 3.1 Schematic representation of the cellular localization of efflux a...](#)

Chapter 4

[Figure 4.1 Key processes determining oral bioavailability, \$f_a\$ = the fraction...](#)

[Figure 4.2 Anatomical structure of the intestinal wall.](#)

[Figure 4.3 The human Cytochrome P450 \(CYP\) “pie”, representing relative abun...](#)

[Figure 4.4 Absolute abundance of Cytochrome P450 \(CYP\) 3A along the human sm...](#)

[Figure 4.5 The human sulfotransferase \(SULT\) “pie”, representing the relativ...](#)

[Figure 4.6 Relative bioavailability between controlled-release \(CR\) and imme...](#)

[Figure 4.7 Villin-corrected expression activity of CYP3A in duodenal biopsy ...](#)

[Figure 4.8 Villin-corrected expression of CYP3A4 in duodenal biopsy samples ...](#)

Chapter 5

[Figure 5.1 Plasma concentration profiles following administration of an imme...](#)

[Figure 5.2 \(a\) Schematic presentation of the star gastric residence drug del...](#)

[Figure 5.3 Profiling during the preformulation stage and early formulation t...](#)

Chapter 6

[Figure 6.1 Approximate position in BCS of marketed MR formulated drugs.](#)

[Figure 6.2 Approximate position in DCS of marketed MR formulated drugs.](#)

[Figure 6.3 Relative colonic fraction absorbed \(\$F_{relColon}\$ \) by DCS class. Box ...](#)

[Figure 6.4 Approximate position in DCS for drugs where regional absorption s...](#)

[Figure 6.5 \$F_{relColon}\$ by ionization state and permeability class. Box and whi...](#)

Chapter 7

[Figure 7.1 Top: sketch of the structure of mesalazine delayed-release delive...](#)

[Figure 7.2 Pharmaceutical pelletization processes.](#)

[Figure 7.3 Spheronization of extrudates into pellets.](#)

[Figure 7.4 Phases of the extrusion process: \(1\) addition of wetted material;...](#)

[Figure 7.5 Illustration of a powder layering process. Powder particles can b...](#)

[Figure 7.6 Fluid bed devices, top spray \(a\), bottom spray \(b\), and rotor-gra...](#)

[Figure 7.7 Growth mechanisms in direct pelletization techniques: \(a\) nucleat...](#)

[Figure 7.8 Mean \(\$n = 6\$ \) piroxicam plasma concentration vs. time profiles of ...](#)

Chapter 8

[Figure 8.1 Schematic representation of the critical steps in oral drug absor...](#)

[Figure 8.2 Solubility of fenofibrate in fasted state simulated intestinal fl...](#)

[Figure 8.3 Schematic diagram of the mechanisms of intestinal drug transport ...](#)

[Figure 8.4 Mechanisms of absorption promoting effects of lipids.](#)

[Figure 8.5 Pharmacokinetic parameters of lovastatin \(100 mg/kg\) after oral a...](#)

[Figure 8.6 Flowchart providing a general guide to lipid-based formulation de...](#)

[Figure 8.7 Ternary phase diagram for \(a\) MCT with Cremophor RH40 and Akoline...](#)

[Figure 8.8 Schematic of dynamic *in vitro* lipolysis model.](#)

[Figure 8.9 Schematic representation of the solubilization and supersaturatio...](#)

[Figure 8.10 Proposed LFCS based on *in vitro* performance evaluations.](#)

Chapter 9

[Figure 9.1 SEM micrographs presenting the morphological transformations of S...](#)

[Figure 9.2 XPS spectra of MPS modified magnetic mesoporous silica nanopartic...](#)

[Figure 9.3 *In vitro* release profiles of drug-loaded diatom silica microparti...](#)

[Figure 9.4 \(A\) *In vitro* dissolution profiles of griseofulvin from griseofulv...](#)

[Figure 9.5 \(A\) *In vitro* release profiles of silybin from \(a\) 72 h-SLB formul...](#)

[Figure 9.6 Plasma concentration profiles of danazol after oral administratio...](#)

[Figure 9.7 Cytotoxic effects of MN-SLB and MN against \(a\) Caco-2 cells or \(b...](#)

[Figure 9.8 TEM images of flat embedded ultrathin sections showing the chitos...](#)

Chapter 10

[Figure 10.1 Schematic representation of multiple unit operations that can be...](#)

[Figure 10.2 Types of dosage forms and the modified-release mechanism.](#)

[Figure 10.3 Applicability of hot-melt extrusion in designing various kinds o...](#)

[Figure 10.4 Release profile of Theophylline with respect to loading from the...](#)

[Figure 10.5 Melt-Spray-Congel process used for the manufacture of Zmax[®]...](#)

[Figure 10.6 Pharmacokinetics of azithromycin from sustained-release micropel...](#)

[Figure 10.7 Effect of processing method on the drug release properties \[45\]...](#)

[Figure 10.8 Effect of insoluble fillers on the *In vitro* drug release \(graph ...](#)

[Figure 10.9 Various downstream processing for melt extrusion to produce powd...](#)

[Figure 10.10 Release profiles of Imatinib mesylate tablet formulations using...](#)

[Figure 10.11 Mean plasma concentration profiles for 800 mg imatinib mesylate...](#)

Chapter 11

[Figure 11.1 Representation of drug release mechanism from sustained-release ...](#)

[Figure 11.2 *In vitro-in vivo* correlation of metoprolol succinate relea...](#)

Chapter 12

[Figure 12.1 Organoleptic test by human test panel: taste masking of ibuprofe...](#)

[Figure 12.2 Water vapor permeability of casted EUDRAGIT[®] films with a l...](#)

[Figure 12.3 Redispersion procedure of anionic poly\(meth\)acrylates: EUDRAGIT[®]...](#)

[Figure 12.4 Dissolution rates of pH-dependent methacrylate films from aqueou...](#)

[Figure 12.5 Elongation at break values: different mixtures of EUDRAGIT[®]](#)

[Figure 12.6 Release profiles of theophylline granules \(dry compacted, 0.3-0....](#)

[Figure 12.7 Release profile modification of EUDRAGIT[®] RL/RS coated theo...](#)

[Figure 12.8 Influence of plasticizer type and amount on the MFFT of aqueous ...](#)

[Figure 12.9 EUDRATEC[®] COL, a pH triggered diffusion-controlled colonic ...](#)

[Figure 12.10 Influence of processing technique on drug release from diprophy...](#)

[Figure 12.11 EUDRATEC[®] ADD dissolution profiles of delayed-release dulo...](#)

Chapter 13

[Figure 13.1 Swellable-Core Technology \(SCT\) tablet architecture and SEM imag...](#)

[Figure 13.2 Dissolution mechanism \(a\) and representative dissolution profile...](#)

[Figure 13.3 Asymmetric-Membrane Technology \(AMT\) tablet architecture and SEM...](#)

[Figure 13.4 Dissolution mechanism \(a\) and representative dissolution profile...](#)

[Figure 13.5 Different spray-layered multiparticulate \(SLM\) formulation archi...](#)

[Figure 13.6 Example of Atazanavir layered-bead coated with various level of ...](#)

[Figure 13.7 Observations of LMP round shape and smooth surface © Capsugel.](#)

[Figure 13.8 Crystalline or solubilized form of a drug within lipid matrix of...](#)

[Figure 13.9 *In vitro* dissolution profile and *in vivo* pharmacokinetic profile...](#)

[Figure 13.10 Main steps of the melt-spray congealing \(MSC\) process © Capsuge...](#)

[Figure 13.11 High-shear granulator \(scheme on left\) used to produce lipid mu...](#)

[Figure 13.12 Quantification of the viable counts of probiotics filled in gel...](#)

[Figure 13.13 Physiological fate of DRcaps[®] after oral administration © ...](#)

[Figure 13.14 Scintigraphy images of key event in the GI transit of enTRinsic...](#)

[Figure 13.15 Plasma concentration versus time profile of enTRinsic[™] enteric ...](#)

[Figure 13.16 MRI scans showing enTRinsic™ capsules localization within the G...](#)

[Figure 13.17 Comparison of small intestinal transit time until disintegratio...](#)

Chapter 14

[Figure 14.1 Simulated velocity vectors \(a\) on a midplane in line with the pa...](#)

[Figure 14.2 \(a\) Contours of velocity magnitude \(m/s\) on midplane in line wit...](#)

[Figure 14.3 CFD-predicted velocity vectors \(m/s\) on the impeller plane \(y-pl...](#)

[Figure 14.4 Phase-resolved velocity fields for positions \(from left to right...](#)

[Figure 14.5 Schematic of flow-through cell showing packed and open column co...](#)

[Figure 14.6 Illustration of rotating beaker with a tablet fixed on a steel w...](#)

[Figure 14.7 Schematic view of the apparatus developed by Burke et al. The de...](#)

[Figure 14.8 Schematic representation of the dynamic gastric model.](#)

[Figure 14.9 3D model of DCM tube. The DCM tube consists of \(a\) a hemispheric...](#)

[Figure 14.10 Biorelevant dissolution stress test device. \(a\) Schematic repre...](#)

[Figure 14.11 Schematic presentation of TIM-1: \(A\) gastric compartment, \(B\) p...](#)

Chapter 15

spray-layered multiparticulates (SLM)
 advantages of [239](#)
 formulation, characterization, and evaluation of [238](#)–239
 manufacturing and process considerations of [239](#)
star gastric residence drug delivery system [91](#)
STELLA™ models [153](#)
stomach, transit and hydrodynamics [26](#)–29
sulfotransferases (SULTs) [68](#)
supersaturable SEDDS (S- SEDDS) [154](#)
supersaturated SNEDDS (super-SNEDDS) [154](#)
surface-modification, silica-based materials [169](#)
surface tension
 gastric [6](#)
 small intestine fluids [14](#)–15
sustained release (SR) drug delivery systems [205](#)–206
sustained-release (SR) formulations [342](#)
Swellable-Core Technology (SCT) tablet architecture [236](#)

t

Talinolol [43](#)
targeted-release (TR) dosage forms [103](#)
telemetric capsules [25](#)
template method, mesoporous silica synthesis
 M41S mesoporous materials [161](#)–162
 SBA mesoporous materials [162](#)

tetraethyl orthosilicate (TEOS) [163](#)
theophylline MR dosage forms [299](#), [300](#)
therapeutic index (TI) drugs [52](#)
therapy-related effects, on GI transit [33](#)
thermodynamic solubility [93](#)
thermoplastic pelletization process [241](#)
time-period, for drug release and absorption [113](#)
TIM systems [268](#), [269](#)
TNO gastrointestinal model (TIM) [310](#)–312
to-be-marketed (TBM) product stage [364](#)
top spray approach [126](#)
total bile acid concentration [22](#)
total gastric volume (TGV) [3](#)
total short-chain fatty acid (SCFA) levels [22](#)
transit time assessment, in human GI tract [25](#), [26](#)
transmission electron microscopy (TEM) [163](#), 164
TravelGuard[®] DuoCap[™] product composition [243](#)
(3-aminopropyl) triethoxysilane (APTES) [162](#)–163
Trokendi XR[®] [412](#)
twin-screw extruders [183](#)

u

undecylenic acid porous silicon (UnPSi) nanoparticles [166](#),
[172](#)
United States Pharmacopoeia (USP) [306](#)

United States Pharmacopoeia (USP) apparatus

 basket apparatus [256](#)

 flow-through cell apparatus [261](#)–263

 paddle apparatus [257](#)–261

 reciprocating cylinder apparatus [261](#)

 reciprocating holder apparatus [263](#)–264

unit impulse response (UIR) [368](#)

uptake transporters [113](#)

 characteristics [41](#)

 at intestinal level [40](#)–42

 regional distribution of [42](#)

 species differences in regional expression [44](#)

uridine 5'-diphosphate glucuronosyltransferases (UGTs) [68](#)

Ussing chambers [45](#), [95](#)

V

virtual bioequivalence (VBE) [364](#)–367

viscosity

 of gastric aspirates [5](#)

 small intestine fluids [15](#)

volume, small intestine fluids [11](#)–12

W

water vapor transmission rate (WVTR) [217](#)

Weibull dissolution function [381](#)–382

Weibull function [446](#)

wet granulation [126](#), [127](#)

whole gut transit time (WGTT) [32](#)

X

X-ray diffraction (XRD) [163](#)

hot-melt extrusion method [196](#)

X-ray photoelectron spectroscopy (XPS) [163](#), [165](#), [197](#)

Z

zero-order release, PK-Sim[®] [381](#)

Zmax[®] [191](#)